Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALMFlexS: Transition to Paliperidone Palmitate in Schizophrenia
NCT01281527Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2010
- Primary completion
- Nov 2012
- Modality
- Metabolically Activated Prodrugs
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Primary endpoint: Positive and Negative Syndrome Scale Total Score at 6 months. Started Nov 2010; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01281527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01281527.